|1.||Fukuyama, Mari: 1 article (01/2010)|
|2.||Ikeda, Yoshimi: 1 article (01/2010)|
|3.||Hori, Hiroshi: 1 article (01/2010)|
|4.||Okuda, Toru: 1 article (01/2010)|
|5.||Fukazawa, Hidesuke: 1 article (01/2010)|
|6.||Suzuki, Takeshi: 1 article (01/2010)|
|7.||Uehara, Yoshimasa: 1 article (01/2010)|
01/01/2010 - "Hypothemycin also inhibited growth factor- and anchorage-independent growth of human cancer cell lines with a constitutively active MEK-ERK pathway. "
10/01/1999 - "Daily treatment of tumor-bearing mice with hypothemycin resulted in significant inhibition of tumor growth. "
10/01/1999 - "Treatment of tumor cells with hypothemycin resulted in reduced expression of Ras-inducible genes, including MMP (matrix metalloproteinase)-1, MMP-9, transforming growth factor-beta (TGF-beta), and vascular endothelial growth factor (VEGF), but not that of the constitutively expressed gene, MMP-2. "
10/01/1999 - "Since MMP-1, MMP-3 and MMP-9 play important roles in tumor invasion and TGF-beta and VEGF are involved in tumor angiogenesis, hypothemycin is considered to be an example of a new class of antitumor drugs, whose antitumor efficacy can be at least partly attributed to inhibition of Ras-inducible genes."
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Transforming Growth Factor beta (TGF-beta)
|3.||Antineoplastic Agents (Antineoplastics)